Audiology findings in patients with teprotumumab associated otologic symptoms
American Journal of Ophthalmology Case Reports, 2021 Purpose: To report a case series of subjective and objective hearing function changes associated with teprotumumab treatment for thyroid eye disease.
Tatiana Correa +2 more
exaly +3 more sources
Audiologic Assessment and Management of Teprotumumab-Associated Ototoxicity: An Updated Narrative Review [PDF]
Audiology ResearchIntroduction: Teprotumumab (Tepezza®), an insulin-like growth factor-1 receptor (IGF-1R) antagonist, is the first FDA-approved targeted therapy for thyroid eye disease (TED).
John Williams +4 more
doaj +2 more sources
Effects of teprotumumab on patients with long-standing, active thyroid eye disease
American Journal of Ophthalmology Case Reports, 2022 Purpose: Describe five cases of long-standing, active thyroid eye disease that responded to treatment with teprotumumab. Observations: Five patients with a greater than 9-month-history of thyroid eye disease, including two patients who had previously ...
Kyle B. Vinson, MD, Maria Kirzhner, MD
exaly +3 more sources
A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease
American Journal of Ophthalmology Case Reports, 2021 Purpose: To present a case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. Observations: A 46-year-old Indian female was treated with teprotumumab (Tepezza) for severe thyroid eye disease within 9 months of diagnosis.
Rona Silkiss, Myra Safo
exaly +3 more sources
Extraocular muscle volume reduction in a patient treated with two courses of teprotumumab for thyroid eye disease [PDF]
American Journal of Ophthalmology Case ReportsPurpose: To report magnetic resonance imaging (MRI) extraocular muscle (EOM) volume analysis in a patient with thyroid eye disease (TED) who was treated with two full courses of teprotumumab.
Hanna Richkind +5 more
doaj +2 more sources
Early experience with teprotumumab for chronic thyroid eye disease
American Journal of Ophthalmology Case Reports, 2020 Purpose: To report the first case of a patient with chronic thyroid eye disease (TED) treated with teprotumumab. Observations: A 50-year-old female with a 3-year history of Graves’ disease presented with bilateral exophthalmos greatest on the left side ...
Don O Kikkawa, Daniel J Ozzello
exaly +3 more sources
Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database [PDF]
Clinical OphthalmologyLouise A Mawn,1 Erin Moore Shriver,2 Madhura Tamhankar,3 Yao Yuan,4 Ann Xi,4 Juan Ayala-Haedo,4 Haridarshan Patel41Department of Ophthalmology, Vanderbilt University Medical Center, Vanderbilt Eye Institute, Nashville, TN, USA; 2Department of ...
Mawn LA +6 more
doaj +2 more sources
American Journal of Ophthalmology Case Reports, 2021 Purpose: To report two cases of thyroid eye disease (TED) associated compressive optic neuropathy (CON) that resolved after treatment with teprotumumab.
Edith R Reshef +2 more
exaly +3 more sources
How to manage thyroid eye disease: recent advances – a narrative review [PDF]
Drugs in ContextThyroid eye disease (TED) is a complex autoimmune disorder and the most common extrathyroidal manifestation of Graves’ disease, characterized by orbital inflammation, tissue remodelling, and varying degrees of functional and cosmetic impairment. Although
Georgios K Markantes +4 more
doaj +2 more sources
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization [PDF]
Laryngoscope Investigative OtolaryngologyObjectives We evaluated the impact of teprotumumab therapy (TT) introduction on orbital decompression (OD) utilization for thyroid eye disease (TED) and compared rates of significant exophthalmos reduction (SER) and diplopia between TT and OD.
Nitish Kumar +5 more
doaj +2 more sources